At what stage in the development of an R&D project should patient organisations qualify as partners?

Edition

At what stage in the development of an R&D project should patient organisations qualify as partners?

There is a general desire for increased involvement of patient organisations in collaborative healthcare projects, as they bring experience, knowledge and real-life assessment to the table. What are the benefits of creating partnerships that cross scientific, academic, advocacy and industry spheres? How early should patient organisations be involved in R&D efforts? How do patient organisations influence the way collaborations are carried? What are the favoured R&D tools involving patients at research scale and what is their acceptance?

Nick Hicks

Head, European Operations
France
Chase Partners LLC

Jane Meijlink

Chairman
The Netherlands
International Painful Bladder Foundation

Berthold Hinzen

Head of Licensing Women’s Health, Radiology & New Spaces
Germany
Bayer Pharmaceuticals

Rebecca Canter

Investment Associate
United Kingdom
Dementia Discovery Fund

Poul Sorensen

Chief Scientific Officer
The Netherlands
Allero Therapeutics
  • No products in the cart.